PharmaLundensis (PHAL) Stock Overview
PharmaLundensis AB operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PHAL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
PharmaLundensis AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.36 |
| 52 Week High | SEK 1.51 |
| 52 Week Low | SEK 0.16 |
| Beta | -0.31 |
| 1 Month Change | 0% |
| 3 Month Change | 1.69% |
| 1 Year Change | -44.62% |
| 3 Year Change | -63.64% |
| 5 Year Change | -90.58% |
| Change since IPO | -90.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHAL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 2.9% | 1.7% |
| 1Y | -44.6% | 30.7% | 19.3% |
Return vs Industry: PHAL underperformed the Swedish Biotechs industry which returned -3.2% over the past year.
Return vs Market: PHAL underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility
| PHAL volatility | |
|---|---|
| PHAL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: PHAL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHAL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1 | Staffan Skogvall | www.pharmalundensis.se |
PharmaLundensis AB operates as a pharmaceutical company. The company develops Iodocarb for treating chronic obstructive pulmonary disease; and treatments for chronic bronchitis and influenza-induced lung failure. It develops EcoFilter, a system that eliminates the release of pharmaceutical drugs and multi-resistant bacteria in hospital wastewater.
PharmaLundensis AB Fundamentals Summary
| PHAL fundamental statistics | |
|---|---|
| Market cap | SEK 15.28m |
| Earnings (TTM) | -SEK 4.40m |
| Revenue (TTM) | n/a |
Is PHAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAL income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 4.40m |
| Earnings | -SEK 4.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 163.1% |
How did PHAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/29 22:36 |
| End of Day Share Price | 2024/01/31 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaLundensis AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.